TIM Participacoes SA (ADR) (NYSE:TSU) declined 6.24% to end last trading session at $8.71. The company on Nov 3, 2015 announced its 3Q15 results.
Data Services remained at solid pace of 41% YoY.
Fixed net revenues showed robust growth of +11% YoY, and +13% YoY in 9M15.
Efficiency Plan on track: Opex (ex towers sale) is down 20% YoY vs. 3Q14.
EBITDA margin (ex towers sale) at 31.5% in 3Q15. EBITDA service margin (excluding the handset business) reached 36.3% in 3Q15.
Capex: Total investments amounted R$1.2 bln in 3Q15 (+22% YoY).
Continental Resources, Inc. (NYSE:CLR) plunged 6.00% to finish last trading session at $22.72. The company on Nov. 4, 2015 announced third quarter 2015 operating and financial results.
Continental reported a net loss of $82.4 million, or $0.22 per diluted share, for third quarter 2015. Adjusted net loss for third quarter 2015 was $43.5 million, or $0.12 per diluted share.
EBITDAX for third quarter 2015 was $472.2 million, compared with EBITDAX of $947.6 million for third quarter 2014. Definitions and reconciliations of adjusted net income and net loss, adjusted earnings per share and EBITDAX to the most directly comparable U.S.
“This was another solid quarter’s performance,” said Harold Hamm, Chairman and Chief Executive Officer. “As expected, we continue to deliver on cost controls and operating efficiencies, while maintaining our exploration focus. We continued in the third quarter to improve across the board in the key metrics we control – faster drill times, lower completed well costs, and strong well results from enhanced completions. On the financial side, we remain focused on balancing capital expenditures with cash flow.”
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) decreased 5.95% to complete last trading session at $156.08. The company on Dec. 17, 2015 announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of obeticholic acid (OCA) in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC). In response to an information request from the FDA, additional clinical data analyses have been submitted. To provide time for a full review of the submission, the original PDUFA date of February 29, 2016 has been extended by three months, resulting in a new PDUFA date of May 29, 2016. The FDA has also notified Intercept of a planned advisory committee meeting date of April 7, 2016.
Intercept is seeking approval of OCA for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.